BRAF突变转移性非小细胞肺癌:意大利生物标志物图谱数据库真实世界数据
该研究基于意大利ATLAS真实世界注册数据库,回顾性纳入244例BRAF突变转移性NSCLC患者(70%为V600E突变),评估临床病理特征、治疗有效性与安全性。一线达拉非尼/曲美替尼(D/T)的中位PFS为19.8个月(95%CI 10.7-29.0),2年OS率65.4%,PFS2为6.6个月(95%CI 0-14.3);D/T活性在性别、吸烟状态及合并MET扩增等亚组间存在差异。
要点
- 一线D/T治疗BRAF V600E突变转移性NSCLC真实世界mPFS为19.8个月,2年OS率65.4%。
- D/T疗效存在性别差异:男性mPFS 13.6个月、2年OS率54.9%;女性mPFS 25.3个月、2年OS率72.3%。
- 合并MET扩增者一线D/T的mPFS较短(13.6个月 vs 无MET扩增44.3个月)。
核心结论
- 真实世界数据证实一线D/T在BRAF V600E突变转移性NSCLC中有效且安全,与既往研究一致,并提示关键临床分子亚组间活性存在差异。
研究设计与样本
- 回顾性真实世界研究,基于意大利ATLAS注册数据库纳入244例BRAF突变转移性NSCLC患者,其中70%为V600E突变。
主要发现
- 一线D/T的中位PFS为19.8个月(95%CI 10.7-29.0),2年OS率为65.4%,PFS2为6.6个月(95%CI 0-14.3)。
- 男性与女性mPFS分别为13.6个月和25.3个月,2年OS率分别为54.9%和72.3%。
- 从不吸烟、既往吸烟和当前吸烟者的mPFS分别为18.4个月、25.6个月和24个月。
- 合并MET扩增者一线D/T的mPFS为13.6个月,无MET扩增者为44.3个月。
临床怎么用
- 一线D/T可作为BRAF V600E突变转移性NSCLC的真实世界治疗选择,但需关注性别、吸烟状态及MET扩增状态对疗效的潜在影响。
局限性
- 研究为回顾性真实世界设计,原文未报告样本量以外的统计效能、P值及多变量校正结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BRAF mutations identify a small subgroup of patients (pts) with non-small cell lung cancer (NSCLC). Dabrafenib/trametinib (D/T) combination is associated with high response rates and durable anti-tumor activity in BRAF-V600-mutants. Several open questions still remain unanswered in clinical practice, including the efficacy of treatments based on clinical and molecular characteristics, the activity in patients with brain metastases, the optimal sequence with immunotherapy-based therapies. Here we present outcomes among advanced BRAF-mutant NSCLC patients from the Italian ATLAS registry. METHODS: Patients with metastatic BRAF-mutated NSCLC were included. Clinical-pathological features, treatment effectiveness and safety outcomes were retrospectively collected from the Italian real-world ATLAS registry. RESULTS: A total of 244 BRAF-mutated NSCLC pts were enrolled, including 70 % V600E mutations. The median PFS of first line D/T was 19.8 months (95 % CI: 10.7-29.0), with a 2-year OS rate of 65.4 % and a PFS2 of 6.6 months (95 % CI: 0-14.3). The activity of D/T differs among sex (mPFS was 13.6 mos and 25.3 mos and 2-yr OS rate were 54.9 % and 72.3 % in males and females, respectively) and smoking status (mPFS was 18.4 mos, 25.6 mos and 24 mos in never, former and current smokers, respectively). Concomitant MET amplification was associated with a shorter median PFS (mPFS was 13.6 mos vs. 44.3 mos with and without MET amplification respectively) in pts treated with D/T as 1st line. CONCLUSIONS: These data confirm the efficacy and safety of first line D/T in BRAF V600E-mutated pts in the real-world setting consistently with prior studies, suggesting a differential activity among key clinical-molecular subgroups.
引用
- Sini C, Russo A, Cortinovis D, et al. Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database. Eur J Cancer. 2025. PMID: 41475048. doi:10.1016/j.ejca.2025.116191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。